NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$179.79
$179.79
50-Day Range
N/A
52-Week Range
$39.82
$179.99
Volume
N/A
Average Volume
1.65 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KITE stock logo

About (KITE) Stock (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

KITE Stock News Headlines

Elon’s New A.I. Device is About to Shock the World
Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”
Elon’s New A.I. Device is About to Shock the World
Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”
Greenup's Kite Day wild and windy
See More Headlines
Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2017
Today
4/30/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:KITE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Arie S. Belldegrun
    Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson
    Chief Financial Officer
  • Cynthia M. Butitta
    Chief Operating Officer
  • David Chang M.D. Ph.D.
    Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim
    Executive Vice President - Business Development
  • Timothy L. Moore
    Executive Vice President - Technical Operations
  • Christine Cassiano
    Senior Vice President - Corporate Communications and Investor Relations

  • Bio & Compensation - 
  • Jian Irish Ph.D.
    Senior Vice President - Supply Chain

  • Bio & Compensation - 
  • Jeffrey Wiezorek M.D.
    Senior Vice President - Clinical Development
  • Shawn Cline Tomasello
    Chief Commercial Officer

KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) issued its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) EPS for the quarter, topping analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to the consensus estimate of $5.74 million. (KITE)'s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.54) EPS.

What other stocks do shareholders of (KITE) own?
This page (NASDAQ:KITE) was last updated on 4/30/2024 by MarketBeat.com Staff

From Our Partners